Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors

Abstract

P-glycoprotein (Pgp), an ATP-dependent transport protein, confers multidrug resistance in cancer cells. Tariquidar binds and inhibits Pgp. To assess the toxicity, pharmacokinetics (PK), and pharmacodynamics of tariquidar, we conducted a phase I trial of tariquidar in combination with doxorubicin, docetaxel, or vinorelbine in children and adolescents with… (More)
DOI: 10.1007/s00280-015-2845-1

Topics

6 Figures and Tables

Cite this paper

@article{Fox2015PharmacokineticAP, title={Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors}, author={Elizabeth Fox and Brigitte C Widemann and Devang Pastakia and Clara C. Chen and Sherry Yang and Diane Cole and Frank M Balis}, journal={Cancer Chemotherapy and Pharmacology}, year={2015}, volume={76}, pages={1273-1283} }